Skip to content
DraconiticResearch
Search Sources API
194,226 studies31 sourcesUpdated 43 min ago
Peer-reviewedCC BY 4.0Frontiers in Immunology

The role of OSMRβ in inflammatory skin diseases

  • Qianqian Zhang1
  • Guifang Qin1
  • Xiaomin Huang1
  • Zudong Meng1
  • Yulin Zou1,2
  1. 1Department of Dermatology, Renmin Hospital, Hubei University of Medicine
  2. 2Department of Dermatology, Venereology and Allergology, University Medical Center Göttingen
Read full textPDFDOICite

Abstract

OSMRβ is a member of the IL-6 cytokine receptor family and plays a critical role in pruritus and immune-mediated skin diseases. Upon inflammatory stimulation, skin immune cells release OSM and IL-31. These cytokines signal through the heterodimeric receptor complexes OSMRβ/gp130 (type II OSM receptor) and OSMRβ/IL-31RA (IL-31 receptor), which are expressed on keratinocytes, fibroblasts, and dorsal root ganglion (DRG) neurons. Engagement of these receptors activates downstream JAK/STAT, MAPK/ERK and PI3K/AKT signaling cascades, leading to itch and inflammation that contributing to the pathogenesis of atopic dermatitis (AD), psoriasis (PSO), prurigo nodularis (PN) and familial primary localized cutaneous amyloidosis (FPLCA). Although a wide range of therapeutic options exist for these diseases, specific targeted treatments remain lacking. Vixarelimab, an OSMRβ-targeting monoclonal antibody, is currently under clinical evaluation for PN and AD.

Related

  1. Circadian orchestration of the cutaneous microenvironment and chronotherapeutic strategies in inflammatory skin diseases
    Wen Zhao, Shanshan Zhang, Yi Deng +5
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0ImmunologyFrontiersCrossref
  2. GLP-1 Receptor Agonists in Chronic Inflammatory Skin Diseases: Immunometabolic Mechanisms and Translational Perspectives
    Klara Andrzejczak, Emilia Kucharczyk, Matylda Korgiel +3
    PharmaceuticsPeer-reviewedCC BY5 citedImmunologyOpenAlex
  3. Mapping the global work-related impact of immune-mediated inflammatory skin diseases: a systematic review
    Fanny Kpenou, Ju Hee Han, Marc Fadel +20
    Journal of Investigative DermatologyPeer-reviewedCC BY 4.0Full textGeneral biologyEpidemiology & public healthHAL
  4. Psychological stress documentation and subsequent risk of chronic inflammatory skin diseases: a large-scale real-world cohort study
    Philip Curman, Emelie Fischer, Jasmina Golaboska +12
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textImmunologyCrossrefEurope PMCPMC
  5. Circulating NET-associated parameters across chronic inflammatory skin diseases: a comparative study
    Joanna Czerwińska, Agnieszka Markiewicz, Alicja Frączek +3
    Frontiers in MedicinePeer-reviewedCC BYFull textImmunologyDOAJ

Cite

BibTeXRIS
BibTeX
@article{zhang2026role,
  title = {{The role of OSMRβ in inflammatory skin diseases}},
  author = {Qianqian Zhang and Guifang Qin and Xiaomin Huang and Zudong Meng and Yulin Zou},
  journal = {Frontiers in Immunology},
  year = {2026},
  month = oct,
  doi = {10.3389/fimmu.2026.1931106},
  url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1931106/full},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - The role of OSMRβ in inflammatory skin diseases
AU  - Qianqian Zhang
AU  - Guifang Qin
AU  - Xiaomin Huang
AU  - Zudong Meng
AU  - Yulin Zou
PY  - 2026
DA  - 2026/10/09
JO  - Frontiers in Immunology
DO  - 10.3389/fimmu.2026.1931106
UR  - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1931106/full
AB  - OSMRβ is a member of the IL-6 cytokine receptor family and plays a critical role in pruritus and immune-mediated skin diseases. Upon inflammatory stimulation, skin immune cells release OSM and IL-31. These cytokines signal through the heterodimeric receptor complexes OSMRβ/gp130 (type II OSM receptor) and OSMRβ/IL-31RA (IL-31 receptor), which are expressed on keratinocytes, fibroblasts, and dorsal root ganglion (DRG) neurons. Engagement of these receptors activates downstream JAK/STAT, MAPK/ERK and PI3K/AKT signaling cascades, leading to itch and inflammation that contributing to the pathogenesis of atopic dermatitis (AD), psoriasis (PSO), prurigo nodularis (PN) and familial primary localized cutaneous amyloidosis (FPLCA). Although a wide range of therapeutic options exist for these diseases, specific targeted treatments remain lacking. Vixarelimab, an OSMRβ-targeting monoclonal antibody, is currently under clinical evaluation for PN and AD.
SN  - 1664-3224
ER  -